EUVIMEDEUVIMED entdecken
Crossref

Alloimmunization as a barrier to gene therapy in sickle cell disease

Hannah R Abrams iD, Nabiha H Saifee iD, William S Miller, Antonio Cortez, Rida A Hasan iD, Sandhya R Panch, Kleber Y Fertrin

Transfusion · 2025

DOI: 10.1111/trf.18266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Hannah R Abrams und 6 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Genetic Therapy, Isoantibodies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alloimmunization is prevalent in patients with sickle cell disease (SCD) and can be a barrier to gene therapy (GT) due to the necessary transfusion support for successful stem cell collection and infusion. We estimate that standard‐of‐care GT for an adult with SCD will require an average of 35–45 units of red blood cells over a 6‐month period. Institutions should actively plan for these transfusion needs and share information to inform national consensus policies on the management of alloimmunization during GT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellGenetic TherapyIsoantibodiesHumansErythrocyte TransfusionAdult

Stichwörter der Autor:innen

RBC transfusioncellular therapygene therapyimmunohematology (RBC serology, blood groups)sickle cell anemia

Substanzen

Isoantibodies

Autor:innen und Institutionen

  • Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Department of Laboratory Medicine and Pathology, Seattle Children's, Seattle, Washington, USA.
  • University of Washington School of Medicine, Seattle, Washington, USA.
  • Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Hannah R Abrams, Nabiha H Saifee, Rida A Hasan

Förderung

  • NCI NIH HHS

Zitieren

APA

Abrams, H. R., Saifee, N. H., Miller, W. S., Cortez, A., Hasan, R. A., Panch, S. R., & Fertrin, K. Y. (2025). Alloimmunization as a barrier to gene therapy in sickle cell disease. Transfusion. https://doi.org/10.1111/trf.18266

Vancouver

Abrams HR, Saifee NH, Miller WS, Cortez A, Hasan RA, Panch SR, et al. Alloimmunization as a barrier to gene therapy in sickle cell disease. Transfusion. 2025. doi:10.1111/trf.18266

BibTeX
@article{Abrams2025,
  author = {Abrams, Hannah R and Saifee, Nabiha H and Miller, William S and Cortez, Antonio and Hasan, Rida A and Panch, Sandhya R and Fertrin, Kleber Y},
  title = {Alloimmunization as a barrier to gene therapy in sickle cell disease},
  journal = {Transfusion},
  year = {2025},
  doi = {10.1111/trf.18266}
}
Kostenlos starten →